# Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)

> **NCT04086472** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 80 (actual)

## Conditions studied

- Respiratory Syncytial Viruses

## Interventions

- **BIOLOGICAL:** Clesrovimab
- **OTHER:** Placebo
- **BIOLOGICAL:** RSV-A Memphis 37b

## Key facts

- **NCT ID:** NCT04086472
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-28
- **Primary completion:** 2020-03-22
- **Final completion:** 2020-08-14
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04086472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04086472, "Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04086472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*